In the long run, defining the mechanisms underlying the interaction of therapeutic antibody Fc and FcγRs as we have reported here will help us to develop therapeutics targeting LILRB4 and other immune checkpoints on myeloid malignancies with greater potency and efficacy. The gene discussed is LILRB4; the disease is myeloid neoplasm.